Compare SKLZ & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKLZ | LPCN |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3M | 61.8M |
| IPO Year | 2020 | 2011 |
| Metric | SKLZ | LPCN |
|---|---|---|
| Price | $2.87 | $6.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $14.00 | ★ $15.00 |
| AVG Volume (30 Days) | 34.6K | ★ 123.9K |
| Earning Date | 05-07-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.98 | ★ 46.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,865,000.00 | $1,976,677.00 |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $12.68 | $74.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.10 | $2.52 |
| 52 Week High | $9.11 | $12.37 |
| Indicator | SKLZ | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 36.50 |
| Support Level | N/A | $2.87 |
| Resistance Level | $3.68 | $10.68 |
| Average True Range (ATR) | 0.18 | 0.67 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 0.00 | 2.11 |
Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. The company's reportable business segments are: the Skillz segment and the Aarki segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is an artificial intelligence company that delivers advertising solutions. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The majority of its revenue is generated from the Skillz segment. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.